Kodiak Sciences (NYSE:KOD) Stock Rating Reaffirmed by Chardan Capital

Chardan Capital reiterated their buy rating on shares of Kodiak Sciences (NYSE:KOD) in a research note published on Monday, AnalystRatings.com reports. They currently have a $40.00 price target on the stock.

Separately, Zacks Investment Research cut Kodiak Sciences from a buy rating to a hold rating in a research report on Tuesday, October 29th.

Shares of NYSE:KOD opened at $51.05 on Monday. Kodiak Sciences has a one year low of $5.65 and a one year high of $72.97. The company has a 50-day simple moving average of $24.07 and a 200-day simple moving average of $15.34.

Kodiak Sciences (NYSE:KOD) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.33).

Several institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Kodiak Sciences by 179.7% during the second quarter. JPMorgan Chase & Co. now owns 6,476 shares of the company’s stock worth $73,000 after purchasing an additional 4,161 shares during the period. Hillsdale Investment Management Inc. purchased a new position in Kodiak Sciences in the 2nd quarter valued at $99,000. Metropolitan Life Insurance Co NY acquired a new position in Kodiak Sciences in the 3rd quarter valued at $131,000. Jacobs Levy Equity Management Inc. acquired a new position in Kodiak Sciences in the 2nd quarter valued at $122,000. Finally, Marshall Wace North America L.P. purchased a new position in Kodiak Sciences during the 1st quarter worth $73,000.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Featured Article: What is a Futures Contract?

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.